中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

38 records (took 0.037 seconds)

    無線電力伝送システム
    1.
    发明专利
    無線電力伝送システム 审中-公开

    公开(公告)号：JP2020162235A

    公开(公告)日：2020-10-01

    申请号：JP2019057378

    申请日：2019-03-25

    Applicant: 河野 隆二 ,  UNIVERSITY OF OULU RESEARCH INSTITUTE JAPAN−CWC日本株式会社 ,  よこはまティーエルオー株式会社

    Inventor： 河野 隆二

    IPC: H02J50/20 ,  H02J50/80 ,  H01Q3/26 ,  H01Q25/00 ,  H02J50/50

    Abstract: 【課題】マイクロ波を用いた無線電力伝送において、給電距離の二乗に比例して電力密度が小さくなることによる、長距離電力伝送の送電効率の低下を低減する。 【解決手段】本発明の無線電力伝送システムは、送電機と受電機の間に中継器を加え、電力を中継させて伝送するマルチホップリレーを用いる。マルチホップリレーを用いて電力を伝送することにより、伝送系統において送電機、受電機、及び中継器の各ノード間の距離が短くなり、伝送距離による減衰の影響は低下する。送電機と受電機の間を直接給電するときと比較して、マルチホップリレーを用いて中継器を介して電力伝送することにより長距離の給電効率が上昇する。また、人体や他の無線機器への干渉を回避する。 【選択図】図1

    METHOD FOR ESTABLISHING RELAY CONNECTIVITY IN ETSI SMARTBAN
    4.
    发明申请
    METHOD FOR ESTABLISHING RELAY CONNECTIVITY IN ETSI SMARTBAN 有权

    公开(公告)号：US20210144804A1

    公开(公告)日：2021-05-13

    申请号：US17096037

    申请日：2020-11-12

    Applicant: University of Oulu

    Inventor： Berhane GEBREMEDHIN ,  Tuomas PASO ,  Jussi HAAPOLA

    IPC: H04W88/04 ,  H04W84/18 ,  H04W84/12 ,  H04L5/00 ,  H04W16/18

    Abstract: The present invention discloses a mechanism to initiate, establish, and maintain relay connectivity in a SmartBAN network while maintaining uninterrupted operations within the network. The present invention comprises the aspects of identifying and notifying an isolated node, initiating and establishing relay connectivity, maintaining the relay connectivity, and ending the relay connectivity when this is desired by either a hub, the isolated node or the nominated relay node. Some new frame formats comprising several new Information Units are also defined.

    1,2,4-triazole derivatives as tankyrase inhibitors
    5.
    发明授权
    1,2,4-triazole derivatives as tankyrase inhibitors 有权

    公开(公告)号：US11926614B2

    公开(公告)日：2024-03-12

    申请号：US17253668

    申请日：2019-06-19

    Applicant: OSLO UNIVERSITETSSYKEHUS HF ,  FORSCHUNGSVERBUND BERLIN E.V. ,  UNIVERSITY OF OULU

    Inventor： Stefan Krauss ,  Marc Nazare ,  Lari Lehtio ,  Jo Waaler ,  Anita Wegert ,  Ruben Gerardus George Leenders

    IPC: C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04

    CPC classification number: C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07B2200/07

    Abstract: The present invention relates to compounds of formula (I), tautomers, stereoisomers, pharmaceutically acceptable salts and pro-drugs thereof, to processes for their preparation, to pharmaceutical compositions containing such compounds and to their use in therapy wherein a dashed line indicates an optional bond; X represents: a 5- or 6-membered, unsaturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), —CN, —NO2, —N(R)2, and —SO2R (where each R is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl); a C3-5 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); or an aryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); Y represents: an aryl or heteroaryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); a 5- or 6-membered, saturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); or a C3-6 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); and Z represents: an aryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), —CN, —NO2, —N(R)2, and —SO2R (where each R is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl); or an unsaturated, 5- to 10-membered mono- or bicyclic heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), —CN, —NO2, —N(R)2, and —SO2R (where each R is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl). These compounds find particular use in the treatment and/or prevention of a disease or disorder responsive to inhibition of tankyrase 1 and/or 2, for example a disorder which is mediated by tankyrase 1 and/or 2 such as cancer.

    Compounds for use in the treatment of cancer
    7.
    发明申请
    Compounds for use in the treatment of cancer 审中-公开

    公开(公告)号：US20190105289A1

    公开(公告)日：2019-04-11

    申请号：US16091551

    申请日：2017-04-06

    Applicant: University of Oulu

    Inventor： Lari Lehtiö ,  Harikanth Venkannagari ,  Bernhard Lüscher ,  Patricia Verheugd

    IPC: A61K31/166 ,  A61K45/06 ,  A61P35/00

    Abstract: It is an aim of the present invention to provide inhibitors of human diphtheria toxin-like ADP-ribosyltransferases, such as ARTD10, for use as a medicine. It is another aim of the invention to provide compounds for use as human mono-ADP-ribosyltransferase (mARTD) inhibitors in vitro. In the present invention, it has been discovered that human ARTD10, which belongs to an enzyme family linked to cancer biology, can be specifically inhibited by the benzamide comprising compounds disclosed in the invention, such as 4,4′-oxydibenzamide.

    TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS.
    10.
    发明申请
    TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS. 审中-公开

    公开(公告)号：WO2022008896A1

    公开(公告)日：2022-01-13

    申请号：PCT/GB2021/051714

    申请日：2021-07-06

    Applicant: GOLDING, Louise ,  OSLO UNIVERSITETSSYKEHUS HF ,  UNIVERSITY OF OULU

    Inventor： KRAUSS, Stefan ,  WAALER, Jo ,  WEGERT, Anita ,  LEENDERS, Ruben Gerardus George ,  LEHTIO, Lari

    IPC: C07D401/14 ,  C07D471/04 ,  A61K31/4196 ,  A61P35/00

    Abstract: The present invention relates to compounds of general formula (I), tautomers, stereoisomers, N-oxides, pharmaceutically acceptable salts and pro-drug thereof, to processes for their preparation, to pharmaceutical compositions containing such compounds and to their use in therapy: wherein: a dashed line indicates an optional bond; X represents: a 5- or 6-membered, unsaturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), -CN, -NO2, -N(R)2, and -SO2R (where each R is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl); a C3-5 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); or an aryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); Y represents: an aryl or heteroaryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); a 5- or 6-membered, saturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); or a C3-6 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); and Z represents: an aryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), -CN, -NO2, -OH, -N(R' )2 (where each R1 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), -SO2R2 (where R2 is H or C1-6 alkyl, e.g. H or C1-3 alkyl), -SO2N(R3)2 (where each R3 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), and -C(0)N(R4)2 (where each R4 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl, or wherein both R4 groups, together with the intervening nitrogen atom, form a 3 to 6 membered saturated heterocyclic ring); or an unsaturated, 5- to 10-membered mono- or bicyclic heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), -CN, -NO2, -OH, -N(R')2 (where each R1 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), -SO2R2 (where R2 is H or C1-6 alkyl, e.g. H or C1-3 alkyl), -SO2N(R3)2 (where each R3 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), and -C(O)N(R4)2 (where each R4 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl, or wherein both R4 groups, together with the intervening nitrogen atom, form a 3 to 6 membered saturated heterocyclic ring); with the proviso: that when the compound is other than an N-oxide of formula (I), Z must be substituted by at least one substituent selected from -OH, -N(R3)2, -SO2N(R3)2 and -C(O)N(R4)2, preferably by at least one substituent selected from -OH, -SO2N(R3)2 and -C(O)N(R4)2. These compounds find particular use in the treatment and/or prevention of a disease or disorder responsive to inhibition of tankyrase 1 and/or 2, for example a disorder which is mediated by tankyrase 1 and/or 2 such as cancer.

Patent Agency Ranking